ATE100320T1 - Verwendung von thromboxan-a2-rezeptorantagonisten zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von hautkrankheiten. - Google Patents

Verwendung von thromboxan-a2-rezeptorantagonisten zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von hautkrankheiten.

Info

Publication number
ATE100320T1
ATE100320T1 AT89116002T AT89116002T ATE100320T1 AT E100320 T1 ATE100320 T1 AT E100320T1 AT 89116002 T AT89116002 T AT 89116002T AT 89116002 T AT89116002 T AT 89116002T AT E100320 T1 ATE100320 T1 AT E100320T1
Authority
AT
Austria
Prior art keywords
treatment
thromboxan
manufacture
pharmaceutical composition
receptor antagonists
Prior art date
Application number
AT89116002T
Other languages
English (en)
Inventor
Lawrence T Friedhoff
Laura L Bolton
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Application granted granted Critical
Publication of ATE100320T1 publication Critical patent/ATE100320T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
AT89116002T 1988-09-01 1989-08-30 Verwendung von thromboxan-a2-rezeptorantagonisten zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von hautkrankheiten. ATE100320T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/239,376 US4925873A (en) 1988-09-01 1988-09-01 Method of treating skin injuries using thromboxane A2 receptor antagonists
EP89116002A EP0357030B1 (de) 1988-09-01 1989-08-30 Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten

Publications (1)

Publication Number Publication Date
ATE100320T1 true ATE100320T1 (de) 1994-02-15

Family

ID=22901897

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89116002T ATE100320T1 (de) 1988-09-01 1989-08-30 Verwendung von thromboxan-a2-rezeptorantagonisten zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von hautkrankheiten.

Country Status (13)

Country Link
US (1) US4925873A (de)
EP (1) EP0357030B1 (de)
JP (1) JPH02108635A (de)
AT (1) ATE100320T1 (de)
AU (1) AU632503B2 (de)
CA (1) CA1337930C (de)
DE (1) DE68912459T2 (de)
DK (1) DK175207B1 (de)
HU (1) HUT51137A (de)
IE (1) IE63799B1 (de)
NZ (1) NZ230505A (de)
PT (1) PT91597B (de)
ZA (1) ZA896558B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5324746A (en) * 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US7910624B1 (en) 1995-03-03 2011-03-22 The Trustees Of Boston University Compositions for the treatment of blood disorders
CA2174737C (en) * 1993-10-29 2008-04-22 Douglas V. Faller Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
UA55374C2 (uk) 1994-10-21 2003-04-15 Нпс Фармасьютікалз, Інк Сполуки, що мають активність по відношенню до рецепторів кальцію
GB9424708D0 (en) * 1994-12-07 1995-02-01 Bristol Myers Squibb Co Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
EP0907631B1 (de) 1996-05-01 2003-06-18 Nps Pharmaceuticals, Inc. Verbindungen , die auf anorganische ionen-rezeptoren wirken
US5994399A (en) * 1997-03-27 1999-11-30 Mckee; Rex N. Method of regenerating collagen-containing tissues with misoprostol
CA2324426A1 (en) * 1998-02-11 1999-08-19 Douglas V. Faller Compositions and methods for the treatment of cystic fibrosis
US7241746B2 (en) * 2003-08-06 2007-07-10 Regena Therapeutics, Lc Method and composition for treating periodontal disease
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
WO2011038224A1 (en) 2009-09-24 2011-03-31 Trustees Of Boston University Methods for treating viral disorders
WO2011072086A1 (en) 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
MY178073A (en) 2011-02-02 2020-10-01 Biotropics Malaysia Berhad Cosmetic non therapeutic use of extracts from ficus deltoidea
JP7373991B2 (ja) 2016-07-15 2023-11-06 ビラクタ セラピューティクス，インク． 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
PH12021552997A1 (en) 2019-05-31 2023-08-14 Viracta Subsidiary Inc Methods of treating virally associated cancers with histone deacetylase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2809377A1 (de) * 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
DE3000377A1 (de) * 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4537981A (en) * 1981-11-09 1985-08-27 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane and 7-oxabicycloheptene compounds
US4416896A (en) * 1982-05-17 1983-11-22 E. R. Squibb & Sons, Inc. 7-Oxabicyclopheptane substituted amino prostaglandin analogs useful in the treatment of thrombolytic disease
US4663336A (en) * 1985-07-01 1987-05-05 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted diamide and its congener prostaglandin analogs useful in the treatment of thrombotic disease
US4673685A (en) * 1986-07-23 1987-06-16 E. R. Squibb & Sons, Inc. Hydroximic acids of 7-oxabicycloheptane substituted ethers and thioethers useful in the treatment of thrombotic disease
US4752616A (en) * 1987-06-29 1988-06-21 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, compositions containing same and method of use

Also Published As

Publication number Publication date
US4925873A (en) 1990-05-15
IE892755L (en) 1990-03-01
EP0357030A2 (de) 1990-03-07
DE68912459D1 (de) 1994-03-03
DK175207B1 (da) 2004-07-12
NZ230505A (en) 1997-03-24
PT91597A (pt) 1990-03-30
DE68912459T2 (de) 1994-08-04
AU632503B2 (en) 1993-01-07
CA1337930C (en) 1996-01-16
DK431589D0 (da) 1989-08-31
DK431589A (da) 1990-03-02
EP0357030B1 (de) 1994-01-19
EP0357030A3 (en) 1990-08-16
PT91597B (pt) 1995-05-04
ZA896558B (en) 1990-05-30
AU4089889A (en) 1990-03-08
HUT51137A (en) 1990-04-28
JPH02108635A (ja) 1990-04-20
IE63799B1 (en) 1995-06-14

Similar Documents

Publication Publication Date Title
ATE100320T1 (de) Verwendung von thromboxan-a2-rezeptorantagonisten zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von hautkrankheiten.
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
DE3855113D1 (de) Verwendung von Buspiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung der Alkoholsucht
ATE187642T1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
ATE99932T1 (de) Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis.
ATE158183T1 (de) Arzneimittel zur behandlung von anxietas
DE3584560D1 (de) Arzneimittelzusammensetzung geeignet zur behandlung oder prophylaxe von herzstoerungen.
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE206914T1 (de) Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
IT9041503A0 (it) Dispositivo per la cura chirurgica dell'ametropia
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
ATE79254T1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
ATE170076T1 (de) Angiotensin ii-antagonisten zur behandlung von viralen erkrankungen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
FI904475A7 (fi) Tymopentiiniä sisältävät koostumukset ihosairauksien hoitamiseksi paik allisesti
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
ATE80998T1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE69530600D1 (de) Verwendung von nk1-rezeptor antagonisten zur zubereitung von arzneimitteln mit kardioregulierender wirkung
ATE78160T1 (de) Verwendung von ''naftidrofuryl'' zur behandlung von neuropathien.
DE68906028D1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
HK1004889A1 (en) Pharmaceutical formulations containing vincamine for treatment of peripheral vascular diseases
ATE56360T1 (de) Zusammensetzung zur herstellung eines arzneimittels zur therapeutischen behandlung von hauttrauma.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee